Examining the Neuronal Dopaminergic Pathway Underlying Sleep Behavior and Related Dopamine Sleep Disorders Mary Beth Putz University of San Diego
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Biased Allosteric Regulation of the Prostaglandin F2α Receptor: From
Biased Allosteric Regulation of the Prostaglandin F2 Receptor: From Small Molecules to Large Receptor Complexes By Eugénie Goupil Department of Pharmacology and Therapeutics McGill University, Montréal, Canada November, 2012 A thesis submitted to McGill in partial fulfillment of the requirements of the degree of Doctor of philosophy Copyright ©Eugénie Goupil, 2012 ''In theory, there is no difference between theory and practice. In practice, there is.'' -Lawrence Peter ''Yogi'' Berra ii Abstract G protein-coupled receptors (GPCRs) represent the largest family of cell surface receptors, and thus some of the most important targets for drug discovery. By binding to the orthosteric site where endogenous ligands bind, agonists and antagonists differentially modulate signals sent downstream from these receptors. New evidence suggests that GPCRs possess topographically distinct or allosteric binding sites, which may differentially modulate agonist- and antagonist-mediated responses to selectively affect distinct signalling pathways coupled to the same receptor. These sites may either positively or negatively regulate receptor activity, depending on the pathway in question, and thus can act as biased ligands, leading to functional selectivity (or ligand-directed signalling). Another way of allosterically regulating GPCR signalling is through receptor oligomerization, which has recently emerged as a common mechanism for regulating receptor function. The GPCR for prostaglandin F2 FP, is implicated in many important physiological responses, such as parturition, smooth muscle cell contraction and blood pressure regulation. Therefore, evaluating the potential use of allosteric modulators of FP to fine-tune PGF2-mediated signals, as well as generating a better understanding of its putative oligomerization partners would be of significant pharmacological and clinical interest. -
Optogenetic Activation of Dopamine Neurons in the Ventral Tegmental Area Induces Reanimation from General Anesthesia
CORE Metadata, citation and similar papers at core.ac.uk Provided by DSpace@MIT Optogenetic activation of dopamine neurons in the ventral tegmental area induces reanimation from general anesthesia Norman E. Taylora,b,c, Christa J. Van Dorta,b,c, Jonathan D. Kennya,c, JunZhu Peia,c, Jennifer A. Guideraa,c, Ksenia Y. Vlasova,c, Justin T. Leea,c, Edward S. Boydenc,d,e,f, Emery N. Browna,b,c,g,h,1,2, and Ken Solta,b,c,1 aDepartment of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, MA 02114; bDepartment of Anaesthesia, Harvard Medical School, Boston, MA 02114; cDepartment of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139; dMedia Lab, Massachusetts Institute of Technology, Cambridge, MA 02139; eMcGovern Institute, Massachusetts Institute of Technology, Cambridge, MA 02139; fDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139; gThe Picower Institute for Learning and Memory, Massachusetts Institute of Technology, Cambridge, MA 02139; and hInstitute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA 02139 Contributed by Emery N. Brown, September 14, 2016 (sent for review February 29, 2016; reviewed by Loren M. Frank, Robert W. Gereau, and Andrew Jenkins) Dopamine (DA) promotes wakefulness, and DA transporter inhibi- There are currently no clinically approved pharmacologic or cir- tors such as dextroamphetamine and methylphenidate are effective cuit-level interventions that can induce active emergence or for increasing arousal and inducing reanimation, or active emer- reanimation from general anesthesia (10). Dopamine (DA) is a gence from general anesthesia. DA neurons in the ventral tegmental neurotransmitter that is well-known to elicit wakefulness (11). -
Phencyclidine: an Update
Phencyclidine: An Update U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol, Drug Abuse and Mental Health Administration Phencyclidine: An Update Editor: Doris H. Clouet, Ph.D. Division of Preclinical Research National Institute on Drug Abuse and New York State Division of Substance Abuse Services NIDA Research Monograph 64 1986 DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administratlon National Institute on Drug Abuse 5600 Fishers Lane Rockville, Maryland 20657 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 NIDA Research Monographs are prepared by the research divisions of the National lnstitute on Drug Abuse and published by its Office of Science The primary objective of the series is to provide critical reviews of research problem areas and techniques, the content of state-of-the-art conferences, and integrative research reviews. its dual publication emphasis is rapid and targeted dissemination to the scientific and professional community. Editorial Advisors MARTIN W. ADLER, Ph.D. SIDNEY COHEN, M.D. Temple University School of Medicine Los Angeles, California Philadelphia, Pennsylvania SYDNEY ARCHER, Ph.D. MARY L. JACOBSON Rensselaer Polytechnic lnstitute National Federation of Parents for Troy, New York Drug Free Youth RICHARD E. BELLEVILLE, Ph.D. Omaha, Nebraska NB Associates, Health Sciences Rockville, Maryland REESE T. JONES, M.D. KARST J. BESTEMAN Langley Porter Neuropsychiatric lnstitute Alcohol and Drug Problems Association San Francisco, California of North America Washington, D.C. DENISE KANDEL, Ph.D GILBERT J. BOTV N, Ph.D. College of Physicians and Surgeons of Cornell University Medical College Columbia University New York, New York New York, New York JOSEPH V. -
Lysergic Acid Diethylamide (LSD) Promotes Social Behavior Through Mtorc1 in the Excitatory Neurotransmission
Lysergic acid diethylamide (LSD) promotes social behavior through mTORC1 in the excitatory neurotransmission Danilo De Gregorioa,b,1, Jelena Popicb,2,3, Justine P. Ennsa,3, Antonio Inserraa,3, Agnieszka Skaleckab, Athanasios Markopoulosa, Luca Posaa, Martha Lopez-Canula, He Qianzia, Christopher K. Laffertyc, Jonathan P. Brittc, Stefano Comaia,d, Argel Aguilar-Vallese, Nahum Sonenbergb,1,4, and Gabriella Gobbia,f,1,4 aNeurobiological Psychiatry Unit, Department of Psychiatry, McGill University, Montreal, QC, Canada, H3A 1A1; bDepartment of Biochemistry, McGill University, Montreal, QC, Canada, H3A 1A3; cDepartment of Psychology, McGill University, Montreal, QC, Canada, H3A 1B1; dDivision of Neuroscience, Vita Salute San Raffaele University, 20132 Milan, Italy; eDepartment of Neuroscience, Carleton University, Ottawa, ON, Canada, K1S 5B6; and fMcGill University Health Center, Montreal, QC, Canada, H3A 1A1 Contributed by Nahum Sonenberg, November 10, 2020 (sent for review October 5, 2020; reviewed by Marc G. Caron and Mark Geyer) Clinical studies have reported that the psychedelic lysergic acid receptor (6), but also displays affinity for the 5-HT1A receptor diethylamide (LSD) enhances empathy and social behavior (SB) in (7–9). Several studies have demonstrated that LSD modulates humans, but its mechanism of action remains elusive. Using a glutamatergic neurotransmission and, indirectly, the α-amino- multidisciplinary approach including in vivo electrophysiology, 3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptors. optogenetics, behavioral paradigms, and molecular biology, the Indeed, in vitro studies have shown that LSD increased the ex- effects of LSD on SB and glutamatergic neurotransmission in the citatory response of interneurons in the piriform cortex following medial prefrontal cortex (mPFC) were studied in male mice. -
Roles for the Uptake 2 Transporter OCT3 in Regulation Of
Marquette University e-Publications@Marquette Biomedical Sciences Faculty Research and Publications Biomedical Sciences, Department of 2-2019 Roles for the Uptake2 Transporter OCT3 in Regulation of Dopaminergic Neurotransmission and Behavior Paul J. Gasser Marquette University, [email protected] Follow this and additional works at: https://epublications.marquette.edu/biomedsci_fac Part of the Neurosciences Commons Recommended Citation Gasser, Paul J., "Roles for the Uptake2 Transporter OCT3 in Regulation of Dopaminergic Neurotransmission and Behavior" (2019). Biomedical Sciences Faculty Research and Publications. 191. https://epublications.marquette.edu/biomedsci_fac/191 Marquette University e-Publications@Marquette Biomedical Sciences Faculty Research and Publications/College of Health Sciences This paper is NOT THE PUBLISHED VERSION; but the author’s final, peer-reviewed manuscript. The published version may be accessed by following the link in the citation below. Neurochemistry International, Vol. 123, (February 2019): 46-49. DOI. This article is © Elsevier and permission has been granted for this version to appear in e-Publications@Marquette. Elsevier does not grant permission for this article to be further copied/distributed or hosted elsewhere without the express permission from Elsevier. Roles for the Uptake2 Transporter OCT3 in Regulation of Dopaminergic Neurotransmission and Behavior Paul J. Gasser Department of Biomedical Sciences, Marquette University, Milwaukee, WI Abstract Transporter-mediated uptake determines the -
Sex Differences in Serotonergic and Dopaminergic Mediation of LSD Discrimination in Rats
Western Michigan University ScholarWorks at WMU Dissertations Graduate College 8-2017 Sex Differences in Serotonergic and Dopaminergic Mediation of LSD Discrimination in Rats Keli A. Herr Western Michigan University, [email protected] Follow this and additional works at: https://scholarworks.wmich.edu/dissertations Part of the Psychology Commons Recommended Citation Herr, Keli A., "Sex Differences in Serotonergic and Dopaminergic Mediation of LSD Discrimination in Rats" (2017). Dissertations. 3170. https://scholarworks.wmich.edu/dissertations/3170 This Dissertation-Open Access is brought to you for free and open access by the Graduate College at ScholarWorks at WMU. It has been accepted for inclusion in Dissertations by an authorized administrator of ScholarWorks at WMU. For more information, please contact [email protected]. SEX DIFFERENCES IN SEROTONERGIC AND DOPAMINERGIC MEDIATION OF LSD DISCRIMINATION IN RATS by Keli A Herr A dissertation submitted to the Graduate College in partial fulfillment of the requirements for the degree of Doctor of Philosophy Psychology Western Michigan University August 2017 Doctoral Committee: Lisa Baker, Ph.D., Chair Cynthia Pietras, Ph.D. Heather McGee, Ph.D. Missy Peet, Ph.D. SEX DIFFERENCES IN SEROTONERGIC AND DOPAMINERGIC MEDIATION OF LSD DISCRIMINATION IN RATS Keli A. Herr, Ph.D. Western Michigan University After decades of opposition, a resurgence of interest in the psychotherapeutic potential of LSD is gaining acceptance in the medical community. Future acceptance of LSD as a psychotherapeutic adjuvant may be predicated on knowledge about its neural mechanisms of action. Preclinical drug discrimination assay offers an invaluable model to determine the neural mechanisms underlying LSD’s interoceptive stimulus effects. -
WHO Technical Meeting on Sleep and Health
WHO technical meeting on sleep and health Bonn Germany, 22-24 January 2004 World Health Organization Regional Office for Europe European Centre for Environment and Health Bonn Office ABSTRACT Twenty-one world experts on sleep medicine and epidemiologists met to review the effects on health of disturbed sleep. Invited experts reviewed the state of the art in sleep parameters, sleep medicine and, long-term effects on health of disturbed sleep in order to define a position on the secondary and long- term effects of noise on sleep for adults, children and other risk groups. This report gives definitions of normal sleep, of indicators of disturbance (arousals, awakenings, sleep deficiency and fragmentation); it describes the main sleep pathologies and disorders and recommends that when evaluating the health impact of chronic long-term sleep disturbance caused by noise exposure, a useful model is the health impact of chronic insomnia. Keywords SLEEP ENVIRONMENTAL HEALTH NOISE Address requests about publications of the WHO Regional Office to: • by e-mail [email protected] (for copies of publications) [email protected] (for permission to reproduce them) [email protected] (for permission to translate them) • by post Publications WHO Regional Office for Europe Scherfigsvej 8 DK-2100 Copenhagen Ø, Denmark © World Health Organization 2004 All rights reserved. The Regional Office for Europe of the World Health Organization welcomes requests for permission to reproduce or translate its publications, in part or in full. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. -
Dyssomnia Sleep Disorders.Pdf
Dyssomnia Sleep Disorders Dyssomnia Sleep Disorders By Yolanda Smith, BPharm Dyssomnia is a broad type of sleep disorders involving difficulty falling or remaining asleep, which can lead to excessive sleepiness during the day due to the reduced quantity, quality or timing of sleep. This is distinct from parasomnias, which involves abnormal behavior of the nervous system during sleep. Symptoms indicative a dyssomnia sleep disorder may include difficulty falling asleep, intermittent awakenings during the night or waking up earlier than usual. As a result of the reduced or disrupted sleep, most patients do not feel well rested and have less ability to perform during the day. In many cases, lifestyle habits have an impact on the disorder, including stress, physical pain or discomfort, napping during the day, bedtime or use of stimulants. Dyssomnia Sleep Disorders There are two main types of dyssomnia sleep disorders according to the origin or cause or the disorder: extrinsic and intrinsic. Both of these are covered in more detail below, in addition to general principles in the diagnosis and treatment of the disorders. Extrinsic dyssomnias are sleep disorders that originate from external causes and may include: Insomnia Sleep apnea Narcolepsy Restless legs syndrome Periodic Limb movement disorder Hypersomnia Toxin-induced sleep disorder Kleine-Levin syndrome Intrinsic dyssomnias are sleep disorders that originate from internal causes and may include: Altitude insomnia Substance use insomnia Sleep-onset association disorder Nocturnal paroxysmal dystonia Limit-setting sleep disorder Diagnosis The differential diagnosis between the types of dyssomnias usually begins with a consultation about the sleep history of the individual, including the onset, frequency and duration of sleep. -
Ventral Tegmental Area Glutamate Neurons: Electrophysiological Properties and Projections
15076 • The Journal of Neuroscience, October 24, 2012 • 32(43):15076–15085 Cellular/Molecular Ventral Tegmental Area Glutamate Neurons: Electrophysiological Properties and Projections Thomas S. Hnasko,1,2,3,4 Gregory O. Hjelmstad,2,3 Howard L. Fields,2,3 and Robert H. Edwards1,2 Departments of 1Physiology and 2Neurology, University of California San Francisco, San Francisco, California 94143, 3Ernest Gallo Clinic and Research Center, Emeryville, California 94608, and 4Department of Neurosciences, University of California San Diego, La Jolla, California 92093 The ventral tegmental area (VTA) has a central role in the neural processes that underlie motivation and behavioral reinforcement. Although thought to contain only dopamine and GABA neurons, the VTA also includes a recently discovered population of glutamate neurons identified through the expression of the vesicular glutamate transporter VGLUT2. A subset of VGLUT2 ϩ VTA neurons corelease dopamine with glutamate at terminals in the NAc, but others do not express dopaminergic markers and remain poorly characterized. Using transgenic mice that express fluorescent proteins in distinct cell populations, we now find that both dopamine and glutamate neurons in the medial VTA exhibit a smaller hyperpolarization-activated current (Ih ) than more lateral dopamine neurons and less ϩ consistent inhibition by dopamine D2 receptor agonists. In addition, VGLUT2 VTA neurons project to the nucleus accumbens (NAc), lateral habenula, ventral pallidum (VP), and amygdala. Optical stimulation of VGLUT2 ϩ projections expressing channelrhodopsin-2 further reveals functional excitatory synapses in the VP as well as the NAc. Thus, glutamate neurons form a physiologically and anatom- ically distinct subpopulation of VTA projection neurons. Introduction well as to the amygdala, septum, hippocampus, and prefrontal Dopamine neurons of the ventral midbrain are classically divided cortex (PFC) (Fields et al., 2007; Ikemoto, 2007). -
Reading List Final 2020
Society of Behavioral Sleep Medicine (SBSM) Reading List The purpose of this document is to provide a reference with content-specific reading options for: 1) those who are preparing for the Diplomate of Behavioral Sleep Medicine (DBSM) exam; 2) participants in a BSM training program; or 3) anyone interested in learning more about a certain topic in BSM. Please note that this list is not intended to serve as a comprehensive study guide for exam preparation. For those preparing for the DBSM exam, we do not anticipate that it is feasible to review all of the materials on this list. At the same time, there may be exam content that is not covered by the materials below. This document is prepared and maintained by the SBSM Education Committee. The SBSM is independent from the organization that oversees the exam itself (Board of Behavioral Sleep Medicine; BBSM), and Education Committee members do not have access to the exam. The readings were not designed to serve as preparatory material for the exam, but to provide an overview of various topics to learners. Thus, the SBSM cannot guarantee that the information presented in the readings is up-to-date and comprehensive for exam preparation. We would love your feedback! If you perceive that any articles did not cover the information in a category, or included inaccurate information, please let us know. If you would like to propose additional articles for inclusion in this list, we will consider these as well. Please email [email protected] with your feedback. Instructions: Click on the number to access the publication reference, which can also be found in the alphabetical reference list below. -
Pharmacology - the Reward Pathway
Pharmacology - The reward pathway All drugs of abuse and dependence share one thing in common. They increase the activity of a neurotransmitter called dopamine in the reward pathway of the brain. Activating this reward pathway, which crosses the limbic region of the brain and connects with the cortex-- that is, it crosses the emotional centre of the brain and connects to the decision-making part of the brain-- will reinforce a behaviour. It does so because it produces a pleasurable feeling. Dopamine is a monoamine. Our mood is affected by the monoamines. There's an association between the altered function of monoamine neurotransmitters such as dopamine in the brain, and disorders such as depression and anxiety. Indeed, drugs that increase the amount of these neurotransmitters are the major medical approach to treating disorders such as depression. Dopamine pathways commence in the brainstem, and project diffusely to the cortex. So that is, they're taking us through parts of the brain associated with feelings, and thoughts, and cognition, and memory, and movement. So dopamine is important in the control of mood and emotion, thought patterns, and the laying down of memories. It's also important in the control of sleep, feeding behaviour, and the control of body temperature. Dopamine is the fuel for intentional behaviours. And it's the fuel for desire. Dopamine says, I want and I desire. Dopamine production is turned on when we're cued by a stimulus paired with a reward, when we're doing something that is good for our survival. For this lecture, there are three main dopamine pathways that we're most interested in. -
Sleep and Dreaming
The Journal of Neuroscience, February 1990, fO(2): 371-382 Feature Article Sleep and Dreaming J. Allan Hobson Laboratory of Neurophysiology, Department of Psychiatry, Harvard Medical School, Boston, Massachusetts 02115 With its increasing emphasis upon functional questions, sleep mals to activate their brains periodically in sleep. The only research has entered a new and exciting third phase. Since sleep exceptions are birds, who show brief REM episodes in the first had never been objectively studied in any detail prior to the few days after hatching. They lose this sleep state as they mature, beginning of its first phase in about 1950, it was to be expected thus paralleling the dramatic decline in sleep-and especially that much of the early work in the field would be descriptive. REM-in all young mammals (Roffwarg et al., 1966). Amphibia (For reviews ofthe early work, see Jouvet, 1972; Moruzzi, 1972.) have none of the sleep features of mammals and, unless their Sleep proved a more complex behavior than such distinguished temperature falls, they remain constantly alert even when im- physiologists as Pavlov (1960) and Sherrington (1955) had imag- mobile and relaxed for long periods of time. ined, and, even today, new discoveries continue to be made, I begin this essay by describing the most recent findings re- especially in the clinical realm. In the second phase of sleep garding sleep function, not only because they are exciting in research, beginning about 1960, specific mechanistic theories their novelty, but because they strongly support some of our began to be enunciated and tested. New cellular and molecular commonsense notions about the importance of sleep.